Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya-Reference-Cited by-同舟云学术

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

Published:2007-01 Issue:1 Volume:25 Page:176-184
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Stoute José A.,Gombe Joash,Withers Mark R.,Siangla Joram,McKinney Denise,Onyango Melanie,Cummings James F.,Milman Jessica,Tucker Kathryn,Soisson Lorraine,Stewart V. Ann,Lyon Jeffrey A.,Angov Evelina,Leach Amanda,Cohen Joe,Kester Kent E.,Ockenhouse Christian F.,Holland Carolyn A.,Diggs Carter L.,Wittes Janet,Gray Heppner D.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference24 articles.

1. Ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden;Breman;Am J Trop Med Hyg,2001

2. Roll back malaria: a failing global health campaign;Yamey;BMJ,2004

3. Age-dependent acquired protection against Plasmodium falciparum in people having 2 years exposure to hyperendemic malaria;Baird;Am J Trop Med Hyg,1991

4. Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic area;Hviid;Expert Rev Mol Med,1998

5. The economic and social burden of malaria;Sachs;Nature,2002

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism;Parasitology International;2024-04

2. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults;Vaccine;2024-04

3. Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate;Expert Review of Vaccines;2023-12-27

4. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial;Frontiers in Immunology;2023-10-16

5. Malaria Vaccines;Infectious Diseases;2023